You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsradipine
Accession NumberDB00270  (APRD00298)
TypeSmall Molecule
GroupsApproved
DescriptionIsradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Structure
Thumb
Synonyms
Dynacirc
Isradipino
Isradipinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isradipinecapsule5 mg/1oralGolden State Medical Supply, Inc.2015-05-06Not applicableUs
Isradipinecapsule2.5 mg/1oralActavis Pharma, Inc.2004-01-05Not applicableUs
Isradipinecapsule2.5 mg/1oralAv Pak2014-01-06Not applicableUs
Isradipinecapsule5 mg/1oralCarilion Materials Management2006-01-05Not applicableUs
Isradipinecapsule5 mg/1oralActavis Pharma, Inc.2006-01-05Not applicableUs
Isradipinecapsule5 mg/1oralAv Pak2014-01-06Not applicableUs
Isradipinecapsule2.5 mg/1oralEpic Pharma, LLC2014-05-15Not applicableUs
Isradipinecapsule2.5 mg/1oralGolden State Medical Supply, Inc.2015-05-06Not applicableUs
Isradipinecapsule5 mg/1oralEpic Pharma, LLC2014-05-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ClivotenItalfarmaco (Italy)
DynaCircNovartis (Hong Kong, Malaysia, Mexico, New Zealand, South Africa, Singapore, Thailand, Turkey, United States)
Dynacirc CRReliant, GlaxoSmithKline
EsradinSigma-Tau (Italy)
LomirNovartis (Austria, Brazil, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Netherlands, Norway, Poland, Russia, Sweden), Sankyo (Belgium, Italy), Daiichi Sankyo (Portugal, Switzerland), Mizar (Spain)
PrescalNovartis (United Kingdom)
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYO1UK1S598
CAS number75695-93-1
WeightAverage: 371.3871
Monoisotopic: 371.148120797
Chemical FormulaC19H21N3O5
InChI KeyInChIKey=HMJIYCCIJYRONP-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
IUPAC Name
3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoxadiazoles. These are organic compounds containing a benzene fused to an oxadiazole ring (a five-membered ring with two carbon atoms, one nitrogen atom, and one oxygen atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxadiazoles
Sub ClassNot Available
Direct ParentBenzoxadiazoles
Alternative Parents
Substituents
  • Dihydropyridinecarboxylic acid derivative
  • Benzoxadiazole
  • Dihydropyridine
  • Benzenoid
  • Hydropyridine
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Oxadiazole
  • Furazan
  • Azole
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.
PharmacodynamicsIsradipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of isradipine result in an overall decrease in blood pressure.
Mechanism of actionIsradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, isradipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives isradipine additional arterial selectivity. At therapeutic sub-toxic concentrations, isradipine has little effect on cardiac myocytes and conduction cells.
Related Articles
AbsorptionIsradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%.
Volume of distributionNot Available
Protein binding95%
Metabolism

Hepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine.

Route of eliminationApproximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces.
Half life8 hours
ClearanceNot Available
ToxicitySymptoms of overdose include lethargy, sinus tachycardia, and transient hypotension. Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Isradipine Action PathwayDrug actionSMP00378
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier-0.8439
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5855
P-glycoprotein inhibitor IInhibitor0.9322
P-glycoprotein inhibitor IIInhibitor0.8669
Renal organic cation transporterNon-inhibitor0.884
CYP450 2C9 substrateNon-substrate0.8522
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6631
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.5158
CarcinogenicityNon-carcinogens0.8043
BiodegradationNot ready biodegradable0.9747
Rat acute toxicity2.3960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8699
hERG inhibition (predictor II)Non-inhibitor0.6895
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
  • Actavis totowa llc
  • Watson laboratories inc
  • Glaxosmithkline llc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral2.5 mg/1
Capsuleoral5 mg/1
Prices
Unit descriptionCostUnit
DynaCirc CR 10 mg 24 Hour tablet5.59USD tablet
Dynacirc cr 10 mg tablet4.41USD tablet
DynaCirc CR 5 mg 24 Hour tablet3.0USD tablet
Dynacirc cr 5 mg tablet2.88USD tablet
DynaCirc 5 mg capsule2.31USD capsule
Isradipine 5 mg capsule2.0USD capsule
DynaCirc 2.5 mg capsule1.59USD capsule
Isradipine 2.5 mg capsule1.39USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168-170 °CNot Available
water solubilityPractically insoluble (< 10 mg/L at 37 °C)Not Available
logP4.28SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.228 mg/mLALOGPS
logP3ALOGPS
logP2ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity100.08 m3·mol-1ChemAxon
Polarizability37.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Fletcher H, Roberts G, Mullings A, Forrester T: An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. J Obstet Gynaecol. 1999 May;19(3):235-8. [PubMed:15512286 ]
  2. Ganz M, Mokabberi R, Sica DA: Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. J Clin Hypertens (Greenwich). 2005 Apr;7(4 Suppl 1):27-31. [PubMed:15858400 ]
  3. Hattori T, Wang PL: Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts. Eur J Med Res. 2006 Mar 27;11(3):93-6. [PubMed:16751108 ]
  4. Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y: Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. Int J Neuropsychopharmacol. 2005 Jun;8(2):203-13. [PubMed:15850499 ]
External Links
ATC CodesC08CA03
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.4 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Isradipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Isradipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Isradipine.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Isradipine.
AcebutololIsradipine may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Isradipine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Isradipine.
AcetazolamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Acetazolamide.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Isradipine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Isradipine.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Isradipine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Isradipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Isradipine.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Isradipine.
AliskirenIsradipine may increase the hypotensive activities of Aliskiren.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Isradipine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Isradipine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Isradipine.
AlosetronThe metabolism of Alosetron can be decreased when combined with Isradipine.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Isradipine.
AlprenololIsradipine may increase the hypotensive activities of Alprenolol.
AmbrisentanIsradipine may increase the hypotensive activities of Ambrisentan.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Isradipine.
AmifostineIsradipine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Isradipine is combined with Amiloride.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Isradipine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Isradipine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Isradipine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Isradipine.
AmlodipineIsradipine may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Isradipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Isradipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isradipine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Isradipine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Isradipine is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Isradipine.
AnagrelideIsradipine may increase the QTc-prolonging activities of Anagrelide.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Isradipine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Isradipine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Isradipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Apraclonidine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Isradipine.
AprepitantThe serum concentration of Isradipine can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Isradipine.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Isradipine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Isradipine.
AripiprazoleAripiprazole may increase the hypotensive activities of Isradipine.
Arsenic trioxideIsradipine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Isradipine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Isradipine.
AsenapineThe metabolism of Asenapine can be decreased when combined with Isradipine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Isradipine.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Isradipine.
AtenololIsradipine may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Isradipine can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Isradipine.
AtosibanThe risk or severity of adverse effects can be increased when Isradipine is combined with Atosiban.
Atracurium besylateIsradipine may increase the neuromuscular blocking activities of Atracurium besylate.
AvanafilThe metabolism of Avanafil can be decreased when combined with Isradipine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Isradipine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Isradipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isradipine is combined with Azilsartan medoxomil.
AzithromycinIsradipine may increase the QTc-prolonging activities of Azithromycin.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Isradipine.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Isradipine.
BarbitalBarbital may increase the hypotensive activities of Isradipine.
BedaquilineIsradipine may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilIsradipine may increase the hypotensive activities of Benazepril.
BendroflumethiazideIsradipine may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Isradipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Isradipine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Isradipine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Isradipine.
BepridilIsradipine may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Isradipine.
BethanidineBethanidine may increase the hypotensive activities of Isradipine.
BexaroteneThe serum concentration of Isradipine can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Isradipine.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Isradipine.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Isradipine.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Isradipine.
BimatoprostIsradipine may increase the hypotensive activities of Bimatoprost.
BisoprololIsradipine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Isradipine.
BortezomibThe metabolism of Isradipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Isradipine can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Isradipine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Isradipine.
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Isradipine.
BretyliumIsradipine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Isradipine.
BrimonidineIsradipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Isradipine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Isradipine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Isradipine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Isradipine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Isradipine.
BudesonideThe metabolism of Budesonide can be decreased when combined with Isradipine.
BumetanideThe risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Isradipine.
BupranololIsradipine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Isradipine.
BupropionThe metabolism of Bupropion can be decreased when combined with Isradipine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Isradipine.
BusulfanThe metabolism of Busulfan can be decreased when combined with Isradipine.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Isradipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Isradipine.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Isradipine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Isradipine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Isradipine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Isradipine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Isradipine.
CanagliflozinThe risk or severity of adverse effects can be increased when Isradipine is combined with Canagliflozin.
CandesartanIsradipine may increase the hypotensive activities of Candesartan.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Isradipine.
CandoxatrilIsradipine may increase the hypotensive activities of Candoxatril.
CaptoprilIsradipine may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Isradipine can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Isradipine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Isradipine.
CaroxazoneCaroxazone may increase the hypotensive activities of Isradipine.
CarteololIsradipine may increase the hypotensive activities of Carteolol.
CarvedilolIsradipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Isradipine.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Isradipine.
CeliprololIsradipine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Isradipine.
CeritinibThe serum concentration of Isradipine can be increased when it is combined with Ceritinib.
CeritinibIsradipine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Isradipine.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Isradipine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Isradipine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Isradipine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Isradipine.
ChloroquineIsradipine may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideIsradipine may increase the hypotensive activities of Chlorothiazide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Isradipine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Isradipine.
ChlorpromazineIsradipine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorthalidoneIsradipine may increase the hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Isradipine.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Isradipine.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Isradipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Isradipine.
CilazaprilIsradipine may increase the hypotensive activities of Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Isradipine.
CimetidineThe serum concentration of Isradipine can be increased when it is combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Isradipine.
CiprofloxacinIsradipine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Isradipine.
CitalopramThe metabolism of Citalopram can be decreased when combined with Isradipine.
ClarithromycinIsradipine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Isradipine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Isradipine can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clevidipine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Isradipine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Isradipine.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Isradipine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Isradipine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Isradipine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Isradipine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Isradipine.
ClonidineIsradipine may increase the hypotensive activities of Clonidine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Isradipine.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Isradipine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Isradipine.
ClotrimazoleThe metabolism of Isradipine can be decreased when combined with Clotrimazole.
ClozapineIsradipine may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Isradipine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Isradipine.
CocaineThe metabolism of Cocaine can be decreased when combined with Isradipine.
CodeineThe metabolism of Codeine can be decreased when combined with Isradipine.
ColchicineThe metabolism of Colchicine can be decreased when combined with Isradipine.
ConivaptanThe serum concentration of Isradipine can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Isradipine.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Isradipine.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Isradipine.
CrizotinibIsradipine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Isradipine can be decreased when combined with Crizotinib.
CryptenamineIsradipine may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Isradipine.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Isradipine.
CyclothiazideIsradipine may increase the hypotensive activities of Cyclothiazide.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Isradipine.
DabrafenibThe serum concentration of Isradipine can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Isradipine.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Isradipine.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Isradipine.
DapagliflozinThe risk or severity of adverse effects can be increased when Isradipine is combined with Dapagliflozin.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Isradipine.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isradipine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Isradipine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Isradipine.
DarunavirThe metabolism of Darunavir can be decreased when combined with Isradipine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Isradipine.
DasatinibThe serum concentration of Isradipine can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Isradipine.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Isradipine.
DebrisoquinIsradipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Isradipine.
DeferasiroxThe serum concentration of Isradipine can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Isradipine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Isradipine.
DeserpidineIsradipine may increase the hypotensive activities of Deserpidine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Isradipine.
DexamethasoneThe serum concentration of Isradipine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Isradipine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dexmedetomidine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Isradipine.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Isradipine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Isradipine.
DiazoxideDiazoxide may increase the hypotensive activities of Isradipine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Isradipine.
DiclofenamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Diclofenamide.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Isradipine.
DigoxinThe metabolism of Digoxin can be decreased when combined with Isradipine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Isradipine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Isradipine.
DiltiazemIsradipine may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Isradipine is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Isradipine is combined with Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Isradipine.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Isradipine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Isradipine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Isradipine.
DolasetronIsradipine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Isradipine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Isradipine.
DorzolamideIsradipine may increase the hypotensive activities of Dorzolamide.
DoxazosinIsradipine may increase the hypotensive activities of Doxazosin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Isradipine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Isradipine.
DoxycyclineThe metabolism of Isradipine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Isradipine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Isradipine.
DroperidolIsradipine may increase the QTc-prolonging activities of Droperidol.
DuloxetineIsradipine may increase the orthostatic hypotensive activities of Duloxetine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Isradipine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Isradipine.
EfavirenzThe serum concentration of Isradipine can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Isradipine.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Isradipine.
EfonidipineIsradipine may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Isradipine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Isradipine.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Isradipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Isradipine is combined with Empagliflozin.
EnalaprilIsradipine may increase the hypotensive activities of Enalapril.
EnalaprilatIsradipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Isradipine can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Isradipine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Isradipine.
EplerenoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Eplerenone.
EpoprostenolIsradipine may increase the hypotensive activities of Epoprostenol.
EprosartanIsradipine may increase the hypotensive activities of Eprosartan.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Isradipine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Isradipine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Isradipine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Isradipine.
ErythromycinIsradipine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Isradipine can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Isradipine.
Eslicarbazepine acetateThe serum concentration of Isradipine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isradipine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Isradipine.
EstazolamThe metabolism of Estazolam can be decreased when combined with Isradipine.
EstradiolThe metabolism of Estradiol can be decreased when combined with Isradipine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Isradipine.
EstramustineThe metabolism of Estramustine can be decreased when combined with Isradipine.
EstroneThe metabolism of Estrone can be decreased when combined with Isradipine.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Isradipine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Isradipine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid.
EthanolThe metabolism of Ethanol can be decreased when combined with Isradipine.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Isradipine.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Isradipine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Isradipine.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Isradipine.
EtoposideThe metabolism of Etoposide can be decreased when combined with Isradipine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Isradipine.
EtravirineThe serum concentration of Isradipine can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Isradipine.
EverolimusThe metabolism of Everolimus can be decreased when combined with Isradipine.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Isradipine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Isradipine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Isradipine.
FelodipineIsradipine may increase the hypotensive activities of Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Isradipine.
FenoldopamIsradipine may increase the hypotensive activities of Fenoldopam.
FentanylThe metabolism of Fentanyl can be decreased when combined with Isradipine.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Isradipine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Isradipine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Isradipine.
FlecainideIsradipine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Isradipine.
FluconazoleThe serum concentration of Isradipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Isradipine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Isradipine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Isradipine.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Isradipine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Isradipine.
FlupentixolIsradipine may increase the QTc-prolonging activities of Flupentixol.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Isradipine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Isradipine.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Isradipine.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Isradipine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Isradipine.
FluvoxamineThe metabolism of Isradipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Isradipine.
FosaprepitantThe serum concentration of Isradipine can be increased when it is combined with Fosaprepitant.
FosinoprilIsradipine may increase the hypotensive activities of Fosinopril.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Isradipine.
FosphenytoinThe metabolism of Isradipine can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Isradipine.
FurazolidoneFurazolidone may increase the hypotensive activities of Isradipine.
FurosemideThe risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide.
Fusidic AcidThe serum concentration of Isradipine can be increased when it is combined with Fusidic Acid.
Gadobenic acidIsradipine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Isradipine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Isradipine.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Isradipine.
GemifloxacinIsradipine may increase the QTc-prolonging activities of Gemifloxacin.
GlipizideThe metabolism of Glipizide can be decreased when combined with Isradipine.
GlyburideThe metabolism of Glyburide can be decreased when combined with Isradipine.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Isradipine.
GoserelinIsradipine may increase the QTc-prolonging activities of Goserelin.
GranisetronIsradipine may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Isradipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Isradipine.
GuanabenzIsradipine may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Isradipine.
GuanethidineIsradipine may increase the hypotensive activities of Guanethidine.
GuanfacineIsradipine may increase the hypotensive activities of Guanfacine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Isradipine.
HaloperidolIsradipine may increase the QTc-prolonging activities of Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Isradipine.
HalothaneThe metabolism of Halothane can be decreased when combined with Isradipine.
HexamethoniumIsradipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Isradipine.
HexobarbitalHexobarbital may increase the hypotensive activities of Isradipine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Isradipine.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Isradipine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Isradipine.
HydralazineIsradipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideIsradipine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Isradipine.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Isradipine.
HydroflumethiazideIsradipine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Isradipine.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Isradipine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Isradipine.
IbutilideIsradipine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Isradipine can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Isradipine resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Isradipine.
IloprostIloprost may increase the hypotensive activities of Isradipine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Isradipine.
ImatinibThe metabolism of Isradipine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Isradipine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Isradipine.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Isradipine.
IndapamideIsradipine may increase the hypotensive activities of Indapamide.
IndenololIsradipine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Indinavir can be decreased when combined with Isradipine.
IndoraminIsradipine may increase the hypotensive activities of Indoramin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Isradipine.
IproclozideIproclozide may increase the hypotensive activities of Isradipine.
IproniazidIproniazid may increase the hypotensive activities of Isradipine.
IrbesartanIsradipine may increase the hypotensive activities of Irbesartan.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Isradipine.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Isradipine.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Isradipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Isradipine.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isoxsuprine.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Isradipine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Isradipine.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Isradipine.
IvacaftorThe serum concentration of Isradipine can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Isradipine.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Isradipine.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Isradipine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Isradipine.
KetamineThe metabolism of Ketamine can be decreased when combined with Isradipine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Isradipine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Isradipine.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Isradipine.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Isradipine.
LabetalolIsradipine may increase the hypotensive activities of Labetalol.
LacidipineIsradipine may increase the hypotensive activities of Lacidipine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Isradipine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Isradipine.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Isradipine.
LatanoprostIsradipine may increase the hypotensive activities of Latanoprost.
LenvatinibIsradipine may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineIsradipine may increase the hypotensive activities of Lercanidipine.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Isradipine.
LeuprolideIsradipine may increase the QTc-prolonging activities of Leuprolide.
LevobunololThe risk or severity of adverse effects can be increased when Isradipine is combined with Levobunolol.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Isradipine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Isradipine.
LevodopaIsradipine may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinIsradipine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Isradipine.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Isradipine.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Isradipine.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Isradipine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Isradipine.
LisinoprilIsradipine may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Isradipine.
LofexidineIsradipine may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Isradipine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Isradipine.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Isradipine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Isradipine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Isradipine.
LosartanIsradipine may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Isradipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Isradipine can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Isradipine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Isradipine.
MacitentanIsradipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium Sulfate.
ManidipineIsradipine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Isradipine is combined with Mannitol.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Isradipine.
MebanazineMebanazine may increase the hypotensive activities of Isradipine.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Isradipine.
MecamylamineIsradipine may increase the hypotensive activities of Mecamylamine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Isradipine.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Isradipine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Isradipine.
MethadoneIsradipine may increase the QTc-prolonging activities of Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Isradipine.
MethazolamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Isradipine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Isradipine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Isradipine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isradipine.
MethyldopaIsradipine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Isradipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Isradipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isradipine.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Isradipine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Isradipine.
MetipranololIsradipine may increase the hypotensive activities of Metipranolol.
MetolazoneIsradipine may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Isradipine.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Isradipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Isradipine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Isradipine.
MianserinThe metabolism of Mianserin can be decreased when combined with Isradipine.
MibefradilIsradipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Isradipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Isradipine.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Isradipine.
MidazolamThe metabolism of Midazolam can be decreased when combined with Isradipine.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Isradipine.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Isradipine.
MinaprineMinaprine may increase the hypotensive activities of Isradipine.
MinoxidilIsradipine may increase the hypotensive activities of Minoxidil.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Isradipine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Isradipine.
MitotaneThe serum concentration of Isradipine can be decreased when it is combined with Mitotane.
MivacuriumIsradipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Isradipine.
ModafinilThe serum concentration of Isradipine can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Isradipine.
MoexiprilIsradipine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Isradipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Isradipine.
MontelukastThe metabolism of Montelukast can be decreased when combined with Isradipine.
MorphineThe metabolism of Morphine can be decreased when combined with Isradipine.
MoxifloxacinIsradipine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineIsradipine may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Isradipine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Isradipine.
NadololIsradipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Isradipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Isradipine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Isradipine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Isradipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Isradipine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Isradipine.
NebivololIsradipine may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Isradipine.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Isradipine.
NesiritideThe risk or severity of adverse effects can be increased when Isradipine is combined with Nesiritide.
NetupitantThe serum concentration of Isradipine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Isradipine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Isradipine.
NicardipineIsradipine may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Isradipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Isradipine.
NifedipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nifedipine.
NiguldipineIsradipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Isradipine.
NilvadipineIsradipine may increase the hypotensive activities of Nilvadipine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Isradipine.
NimodipineNimodipine may increase the hypotensive activities of Isradipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Isradipine.
NisoldipineIsradipine may increase the hypotensive activities of Nisoldipine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Isradipine.
NitrendipineIsradipine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Isradipine is combined with Nitroglycerin.
NitroprussideIsradipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Isradipine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Isradipine.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Isradipine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Isradipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Isradipine.
ObinutuzumabIsradipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Isradipine.
OfloxacinIsradipine may increase the QTc-prolonging activities of Ofloxacin.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Isradipine.
OlaparibThe metabolism of Isradipine can be decreased when combined with Olaparib.
OlmesartanIsradipine may increase the hypotensive activities of Olmesartan.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Isradipine.
OmapatrilatIsradipine may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Isradipine.
OndansetronIsradipine may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Isradipine.
OsimertinibThe serum concentration of Isradipine can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Isradipine.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Isradipine.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Isradipine.
OxprenololIsradipine may increase the hypotensive activities of Oxprenolol.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Isradipine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Isradipine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Isradipine.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Isradipine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Isradipine.
PalbociclibThe serum concentration of Isradipine can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Isradipine.
PaliperidoneIsradipine may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Isradipine.
PanobinostatIsradipine may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Isradipine.
PapaverineThe risk or severity of adverse effects can be increased when Isradipine is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Isradipine.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Isradipine.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Isradipine.
PargylineIsradipine may increase the hypotensive activities of Pargyline.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Isradipine.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Isradipine.
PazopanibIsradipine may increase the QTc-prolonging activities of Pazopanib.
PenbutololIsradipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Isradipine.
PentamidineIsradipine may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Isradipine.
PentoliniumIsradipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Isradipine.
PerampanelThe metabolism of Perampanel can be decreased when combined with Isradipine.
PerflutrenIsradipine may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Isradipine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Isradipine.
PerindoprilIsradipine may increase the hypotensive activities of Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Isradipine.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Isradipine.
PethidineThe metabolism of Pethidine can be decreased when combined with Isradipine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Isradipine.
PhenelzinePhenelzine may increase the hypotensive activities of Isradipine.
PheniprazinePheniprazine may increase the hypotensive activities of Isradipine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Isradipine.
PhenoxybenzamineIsradipine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Isradipine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Isradipine.
PhentolamineIsradipine may increase the hypotensive activities of Phentolamine.
PhenytoinThe metabolism of Isradipine can be increased when combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Isradipine.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Isradipine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Isradipine.
PinacidilIsradipine may increase the hypotensive activities of Pinacidil.
PindololIsradipine may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Isradipine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Isradipine.
PirlindolePirlindole may increase the hypotensive activities of Isradipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Isradipine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Isradipine.
PolythiazideIsradipine may increase the hypotensive activities of Polythiazide.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Isradipine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Isradipine.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Isradipine.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Isradipine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Isradipine.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Isradipine.
PrazepamThe metabolism of Prazepam can be decreased when combined with Isradipine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Isradipine.
PrazosinIsradipine may increase the hypotensive activities of Prazosin.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Isradipine.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Isradipine.
PrimaquineIsradipine may increase the QTc-prolonging activities of Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Isradipine.
ProcainamideIsradipine may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Isradipine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Isradipine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Isradipine.
PromazineIsradipine may increase the QTc-prolonging activities of Promazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Isradipine.
PropofolThe metabolism of Propofol can be decreased when combined with Isradipine.
PropranololIsradipine may increase the hypotensive activities of Propranolol.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Isradipine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Isradipine.
QuetiapineThe risk or severity of adverse effects can be increased when Isradipine is combined with Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Isradipine.
QuinaprilIsradipine may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Quinidine can be decreased when combined with Isradipine.
QuinineQuinine may increase the hypotensive activities of Isradipine.
QuinineThe metabolism of Quinine can be decreased when combined with Isradipine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Isradipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Isradipine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Isradipine.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Isradipine.
RamiprilRamipril may increase the hypotensive activities of Isradipine.
RanolazineThe metabolism of Isradipine can be decreased when combined with Ranolazine.
RapacuroniumIsradipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Isradipine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Isradipine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Isradipine.
RemikirenRemikiren may increase the hypotensive activities of Isradipine.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Isradipine.
RescinnamineIsradipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Isradipine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Isradipine.
RifabutinThe metabolism of Isradipine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Isradipine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Isradipine can be increased when combined with Rifapentine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Isradipine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Isradipine.
RiociguatIsradipine may increase the hypotensive activities of Riociguat.
RisperidoneIsradipine may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Isradipine.
RituximabIsradipine may increase the hypotensive activities of Rituximab.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Isradipine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Isradipine.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Isradipine.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Isradipine.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Isradipine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Isradipine.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Isradipine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Isradipine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Isradipine.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Isradipine.
SafrazineSafrazine may increase the hypotensive activities of Isradipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Isradipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Isradipine.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Isradipine.
SaprisartanIsradipine may increase the hypotensive activities of Saprisartan.
SaquinavirIsradipine may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Isradipine can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Isradipine.
SecobarbitalSecobarbital may increase the hypotensive activities of Isradipine.
SelegilineSelegiline may increase the hypotensive activities of Isradipine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Isradipine.
SelexipagIsradipine may increase the hypotensive activities of Selexipag.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Isradipine.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Isradipine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Isradipine.
SertralineThe metabolism of Sertraline can be decreased when combined with Isradipine.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Isradipine.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Isradipine.
SildenafilSildenafil may increase the antihypertensive activities of Isradipine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Isradipine.
SilodosinSilodosin may increase the hypotensive activities of Isradipine.
SilodosinThe metabolism of Silodosin can be decreased when combined with Isradipine.
SiltuximabThe serum concentration of Isradipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Isradipine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Isradipine.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Isradipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Isradipine.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Isradipine.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Isradipine.
SitaxentanIsradipine may increase the hypotensive activities of Sitaxentan.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Isradipine.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Isradipine.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Isradipine.
SotalolThe risk or severity of adverse effects can be increased when Isradipine is combined with Sotalol.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Isradipine.
SpiraprilIsradipine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Spironolactone.
St. John's WortThe serum concentration of Isradipine can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe serum concentration of Isradipine can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Isradipine.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Isradipine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Isradipine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Isradipine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Isradipine.
SulfisoxazoleIsradipine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Isradipine can be decreased when combined with Sulfisoxazole.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Isradipine.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Isradipine.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Isradipine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Isradipine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Isradipine.
TadalafilTadalafil may increase the antihypertensive activities of Isradipine.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Isradipine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Isradipine.
TamsulosinTamsulosin may increase the hypotensive activities of Isradipine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Isradipine.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Isradipine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Isradipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Isradipine.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Isradipine.
TelavancinIsradipine may increase the QTc-prolonging activities of Telavancin.
TelithromycinIsradipine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Isradipine can be decreased when combined with Telithromycin.
TelmisartanIsradipine may increase the hypotensive activities of Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Isradipine.
TemocaprilIsradipine may increase the hypotensive activities of Temocapril.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Isradipine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Isradipine.
TerazosinTerazosin may increase the hypotensive activities of Isradipine.
TerazosinThe risk or severity of adverse effects can be increased when Isradipine is combined with Terazosin.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Isradipine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Isradipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Isradipine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Isradipine.
TerlipressinIsradipine may increase the hypotensive activities of Terlipressin.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Isradipine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Isradipine.
TetrabenazineIsradipine may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Isradipine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Isradipine.
ThiamylalThiamylal may increase the hypotensive activities of Isradipine.
ThiopentalThiopental may increase the hypotensive activities of Isradipine.
ThioridazineIsradipine may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Isradipine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Isradipine.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Isradipine.
TiboloneIsradipine may increase the hypotensive activities of Tibolone.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Isradipine.
TiclopidineThe metabolism of Isradipine can be decreased when combined with Ticlopidine.
TicrynafenIsradipine may increase the hypotensive activities of Ticrynafen.
TimololIsradipine may increase the hypotensive activities of Timolol.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Isradipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Isradipine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Isradipine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Isradipine.
TizanidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Tizanidine.
TocilizumabThe serum concentration of Isradipine can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Isradipine.
TolazolineIsradipine may increase the hypotensive activities of Tolazoline.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Isradipine.
ToloxatoneToloxatone may increase the hypotensive activities of Isradipine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Isradipine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Isradipine.
TorasemideTorasemide may increase the hypotensive activities of Isradipine.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Isradipine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Isradipine.
TramadolThe metabolism of Tramadol can be decreased when combined with Isradipine.
TrandolaprilIsradipine may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Isradipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Isradipine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Isradipine.
TravoprostIsradipine may increase the hypotensive activities of Travoprost.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Isradipine.
TreprostinilIsradipine may increase the hypotensive activities of Treprostinil.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Isradipine.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Isradipine.
TriamtereneThe risk or severity of adverse effects can be increased when Isradipine is combined with Triamterene.
TriazolamThe metabolism of Triazolam can be decreased when combined with Isradipine.
TrichlormethiazideIsradipine may increase the hypotensive activities of Trichlormethiazide.
TrimazosinIsradipine may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Isradipine.
TrimethaphanIsradipine may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Isradipine.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Isradipine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Isradipine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Isradipine.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Isradipine.
UdenafilUdenafil may increase the antihypertensive activities of Isradipine.
UdenafilThe metabolism of Udenafil can be decreased when combined with Isradipine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Isradipine.
UnoprostoneIsradipine may increase the hypotensive activities of Unoprostone.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Isradipine.
ValsartanValsartan may increase the hypotensive activities of Isradipine.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Isradipine.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Isradipine.
VardenafilVardenafil may increase the antihypertensive activities of Isradipine.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Isradipine.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Isradipine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Isradipine.
VerapamilThe risk or severity of adverse effects can be increased when Isradipine is combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Isradipine.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Isradipine.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Isradipine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Isradipine.
VincristineThe metabolism of Vincristine can be decreased when combined with Isradipine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Isradipine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Isradipine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Isradipine.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Isradipine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Isradipine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Isradipine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Isradipine.
XylometazolineIsradipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Isradipine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Isradipine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Isradipine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Isradipine.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Isradipine.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Isradipine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Isradipine.
ZiprasidoneThe metabolism of Isradipine can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Isradipine.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Isradipine.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Isradipine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Isradipine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Isradipine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Berjukow S, Marksteiner R, Gapp F, Sinnegger MJ, Hering S: Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation. J Biol Chem. 2000 Jul 21;275(29):22114-20. [PubMed:10766758 ]
  2. Hitzl M, Striessnig J, Neuhuber B, Flucher BE: A mutation in the beta interaction domain of the Ca(2+) channel alpha(1C) subunit reduces the affinity of the (+)-[(3)H]isradipine binding site. FEBS Lett. 2002 Jul 31;524(1-3):188-92. [PubMed:12135765 ]
  3. Zuhlke RD, Bouron A, Soldatov NM, Reuter H: Ca2+ channel sensitivity towards the blocker isradipine is affected by alternative splicing of the human alpha1C subunit gene. FEBS Lett. 1998 May 8;427(2):220-4. [PubMed:9607315 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Koschak A, Reimer D, Huber I, Grabner M, Glossmann H, Engel J, Striessnig J: alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6. Epub 2001 Apr 2. [PubMed:11285265 ]
  2. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23